The Latest Breaking News from Eli Lilly

Johnson & Johnson (NYSE: JNJ) reported upbeat earnings for its second quarter, but lowered its FY22 guidance. Investors, meanwhile, focused on some notable insider trades.

The Biotech industry has gained significant momentum since the pandemic. Moreover, the industry’s prospects look bright amid the lucrative federal funding and solid investments in breakthrough developments. Thus, given the stock market volatility, it could be wise to invest in quality biotech stocks Eli Lilly (LLY) and Jazz Pharmaceuticals (JAZZ),…

The Dow Jones Industrial Average rose Friday after the index staged its worst first-half performance since 1962. Chinese EV stocks reported strong sales.

The Dow Jones Industrial Average dived 575 points Thursday after a key inflation reading, threatening to extend this week's losses.

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 21.93% on an annualized basis producing an average annual return of 31.32%. Currently, Eli Lilly has a market capitalization of $307.03 billion.

The Dow Jones led the upside, while the Nasdaq and S&P 500 struggled to turn positive. Medical stocks continued to outperform.

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Dow Jones Industrial Average rose 200 points Tuesday, looking to rebound from Monday's losses. Nike stock tumbled on weak guidance.

Dow Jones futures were higher after Monday's stock market fall. Tesla sales are due out amid the new stock market rally.